Mario Balsa: The Impact of PAM50-based Prosigna in Neoadjuvant Planning for Early Breast Cancer
Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology, shared a post on X, about a recent article by C. Corti et al. published in ESMO Open:
“Prospective data on the impact of PAM50-based Prosigna in neoadjuvant planning for HR+/HER2– early breast cancer (n=54)
Treatment plan changed in 35.2%
- Confidence ↑ in 83.7% of physicians
- Anxiety ↓ in 62.5% of patients
Prosigna may guide pre-operative decision-making, not just post.
Know your subtype before you prescribe the hype!
Congrats to Chiara Corti, Sara Tolaney, Pedro Exman, Dana-Farber’s Breast Oncology Center, Nancy Lin, Nabihah Tayob, and all the team!”
Title: Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study
Journal: ESMO Open
Authors: C. Corti, X. Chu, P. Exman, D.M. Kline, N.M. Priedigkeit, E.L. Mayer, A.G. Waks, M.E. Hughes, D.L. Abravanel, A. Giordano, G. Curigliano, N.U. Lin, T.A. King, R.M. Jeselsohn, D.K. Manning, D.A. Dillon, E.A. Mittendorf, N. Tayob, S.M. Tolaney
More posts featuring Mario Balsa on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023